Novavax
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
- Conditions
- COVID-19
- Interventions
- Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)Other: Placebo
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novavax
- Target Recruit Count
- 3600
- Registration Number
- NCT05468736
- Locations
- 🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Advanced Research Center, Anaheim, California, United States
🇺🇸Coast Clinical Research, LLC, Bellflower, California, United States
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Novavax
- Target Recruit Count
- 911
- Registration Number
- NCT05463068
- Locations
- 🇺🇸
Long Beach Clinical Trial Services Inc., Long Beach, California, United States
🇺🇸Benchmark Research, Houston, Texas, United States
🇺🇸Accel Clinical Research, DeLand, Florida, United States
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
- Conditions
- COVID-19SARS CoV 2 Infection
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Novavax
- Target Recruit Count
- 1340
- Registration Number
- NCT05372588
- Locations
- 🇦🇺
Paratus Clinical Research Canberra, Bruce, Australian Capital Territory, Australia
🇦🇺Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Emeritus Research, Camberwell, Victoria, Australia
A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Novavax
- Target Recruit Count
- 384
- Registration Number
- NCT05112848
- Locations
- 🇿🇦
KwaPhila Health Solutions (Enhancing Care), Westridge, Durban, South Africa
🇿🇦Josha Research, Bloemfontein, Free State, South Africa
🇿🇦The Aurum Institute Pretoria Clinical Research Services, Pretoria, Gauteng, South Africa
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
- Conditions
- Covid19
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Novavax
- Registration Number
- NCT05029856
- Locations
- 🇦🇺
Australian Clinical Research Network (ACRN), Maroubra, New South Wales, Australia
🇦🇺Holdsworth House Medical Practice - Sydney, Sydney, New South Wales, Australia
🇦🇺University Hospital Geelong-Barwon Health, Geelong, Victoria, Australia
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
- Conditions
- Covid19SARS-CoV Infection
- Interventions
- Biological: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 AdjuvantBiological: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Novavax
- Target Recruit Count
- 637
- Registration Number
- NCT04961541
- Locations
- 🇦🇺
Paratus Clinical Research - Canberra, Bruce, Australian Capital Territory, Australia
🇦🇺Paratus Clinical Research - Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
- Conditions
- SARS-CoV InfectionCovid19
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Novavax
- Target Recruit Count
- 33000
- Registration Number
- NCT04611802
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, Llc (Pediatric Site), Birmingham, Alabama, United States
🇺🇸Accel Research Sites (Adult Site), Birmingham, Alabama, United States
🇺🇸Central Research Associates, Inc (Pediatric Site), Birmingham, Alabama, United States
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Other: PlaceboBiological: SARS-CoV-2 rS/Matrix M1-AdjuvantBiological: Licensed seasonal influenza vaccine
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Novavax
- Target Recruit Count
- 15185
- Registration Number
- NCT04583995
- Locations
- 🇬🇧
Belfast Health and Social Care Trust (BHSCT) (Site UK011), Belfast, Antrim, United Kingdom
🇬🇧Synexus Midlands Clinical Research Centre (Site UK024), Edgbaston, Birmingham, United Kingdom
🇬🇧The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Novavax
- Target Recruit Count
- 4422
- Registration Number
- NCT04533399
- Locations
- 🇿🇦
ZA018, Bloemfontein, Free State Of South Africa, South Africa
🇿🇦ZA003, Hillbrow, Gauteng, South Africa
🇿🇦Site ZA001, Johannesburg, Gauteng, South Africa
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
- Conditions
- COVID-19
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Novavax
- Target Recruit Count
- 1419
- Registration Number
- NCT04368988
- Locations
- 🇺🇸
Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2, Savannah, Georgia, United States
🇺🇸Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2, Meridian, Idaho, United States
🇺🇸Alliance for Multispecialty Research, LLC - Phase 2, Wichita, Kansas, United States